BC Extra | Feb 1, 2020
Financial News

Arcutis gains in this year’s third biotherapeutic IPO on NASDAQ

The aftermarket performance of two IPOs in January’s final week suggests investors’ appetite for new biotech listings remains robust. In NASDAQ’s third biotherapeutic IPO of the year, dermatology company Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) raised $159.4...
BC Extra | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

Future Ventures leads Deep Genomics’ $40M series B   Looking to submit INDs for two programs this year, Deep Genomics Inc. raised $40 million in a series B round led by Future Ventures, with participation...
BC Extra | Oct 22, 2019
Financial News

Crossover investors help Arcutis raise $95M to advance PDE-4 inhibitor for psoriasis

Arcutis raised $94.5 million in a series C financing to advance lead product ARQ-151, a topical formulation of the PDE-4 inhibitor roflumilast, through Phase III trials for mild-to-moderate psoriasis. Arcutis Biotherapeutics Inc. co-founder Chairman Bhaskar...
BC Extra | Jul 22, 2019
Clinical News

July 22 Clinical Quick Takes: Positive psoriasis data for Arcutis; plus Intec and Renovo

ARQ-151 meets Phase IIb endpoint  Arcutis Inc. (Westlake Village, Calif.) said high and low daily doses of ARQ-151 for six weeks met the primary endpoint in a Phase IIb trial of reducing signs of plaque...
BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics. Frazier Healthcare launched the company in 2016...
Items per page:
1 - 5 of 5